| |

Diabetes Drug Triggers Mesothelioma Cell Death in New Study

ByAlex Strauss

diabetes drugA new study suggests that the diabetes drug metformin may help keep mesothelioma cells from growing and spreading. 

The study is not the first study of metformin for mesothelioma. But this one dives deeper into how the diabetes drug may actually work against asbestos cancer. 

Drugs to treat mesothelioma can be expensive. But metformin pills are common and relatively cheap. If the drug proves to be helpful against mesothelioma, it could offer hope to thousands of patients fighting this rare cancer. 

Mesothelioma Treatment with a Diabetes Drug?

Pleural mesothelioma is a rare form of lung cancer caused by asbestos. It affects the thin tissue surrounding the lungs. 

As cancer grows on this membrane, it prevents the natural movement of the lungs. Pleural mesothelioma patients often develop chest pain, cough, and breathing problems. This cancer spreads quickly. Even with the best standard treatments, many patients die within a year of diagnosis. 

Metformin is the main Type 2 diabetes drug. But some animal studies show it may also be effective against some cancers. Metformin helps regulate cell communication and proliferation. It does this through a protein pathway scientists call Notch. 

Doctors know that when the Notch pathway is not working right, cells can grow out of control. Researchers hope the diabetes drug can slow or stop this process in mesothelioma.

Results of the Metformin Study

For the diabetes drug to work against pleural mesothelioma, there needs to be a problem with the Notch pathway. When researchers at Italy’s University of Ferrara tested pleural mesothelioma cells, that is exactly what they found. 

“MPM [malignant pleural mesothelioma] cells showed high levels of Notch1 activation compared to normal pleural mesothelial cells,” writes lead study author Marika Rossini. 

When researchers treated the cells with the diabetes drug, they got the reaction they were hoping for. “Metformin treatment hampered MPM cell proliferation and enhanced the apoptotic process, accompanied by decreased Notch1 activation,” says Dr. Rossini. 

Apoptosis is the process by which aging cells self-destruct and are replaced by fresh, healthy cells. Apoptosis slows way down or stops in mesothelioma cells. This allows too many cells to grow in one area, forming a tumor. 

Scientists will need to conduct more studies to know for sure if the diabetes drug will help human mesothelioma patients. But these results suggest that it is possible. 

Source:

Rossini, M, et al, “Metformin Induces Apoptosis and Inhibits Notch1 in Malignant Pleural Mesothelioma Cells”, January 18, 2021, Frontiers in Cell Developmental Biology, https://www.frontiersin.org/articles/10.3389/fcell.2020.534499/full

 

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    ByAlex Strauss

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    ByAlex Strauss

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    ByAlex Strauss

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | |

    A Second-Line Option for Mesothelioma?

    ByAlex Strauss

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • | |

    Repeat HIPEC Improves Mesothelioma Survival

    ByAlex Strauss

    If one cytoreductive surgery and HIPEC procedure for mesothelioma is good, subsequent treatments may be even better. That is the central message of research conducted at the Moffitt Cancer Center in Florida. The study’s aim was to assess overall survival among peritoneal mesothelioma patients who had not just one, but two or more rounds of heated intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery. The cytoreduction/HIPEC approach has become popular for peritoneal mesothelioma, a treatment-resistant cancer of abdominal membranes caused by asbestos. Cytoreductive surgery involves removing as much of the mesothelioma tumor as possible from the abdomen. Because the shape and spreading pattern of mesothelioma tumors make complete cytoreduction difficult, the surgery is often followed by a rinse with a heated solution…

  • | |

    Value of Mesothelioma Surgery Challenged for Healthy Patients

    ByAlex Strauss

    New research conducted in Italy and presented at the 15th World Conference on Lung Cancer in Sydney, Australia suggests that mesothelioma surgery – no matter what kind – may not offer a survival advantage over medical management for the healthiest of patients. Mesothelioma is a rare but aggressive malignancy that is highly resistant to standard cancer treatments. The two types of mesothelioma surgery considered to be options for people with resectable cancer are pleurectomy decortication (P/D) or extrapleural pneumonectomy (EPP). While EPP is more radical than P/D because it involves removing a lung, both carry a heavy risk of complications and, according to the Italian researchers, may not be of value for certain patients. The study reviewed data from 1,365…